Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Core Insights - Science 37 is enhancing patient recruitment and enrollment for clinical trials, particularly for a Phase 2 trial evaluating EP547 in patients with Cholestatic Pruritus due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis [1] - The company offers standalone patient recruitment services or in combination with its Metasite™ to improve enrollment efforts for clinical research sponsors and CROs [2] - Science 37's mission is to accelerate clinical research by providing universal trial access, utilizing proprietary technology and expert teams to enhance the quality of patient recruitment [6] Enrollment Performance - Science 37 contributed 21% of all randomized study participants from September 2022 to April 2024, surpassing its contracted enrollment goal [7] - The average enrollment rate achieved by Science 37 was 1 patient per month, significantly higher than the 0.1 patients per month rate at traditional sites [7] Recruitment Strategy - Traditional recruitment methods are limited by geography, while Science 37 can recruit patients from anywhere, which is crucial for rare disease research [5] - The company rigorously qualifies patients before referring them to traditional trial sites, expanding the reach of clinical trials [6]